Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Firocoxib is a selective cyclooxygenase-2 (COX-2) inhibitor belonging to the coxib class of nonsteroidal anti-inflammatory drugs (NSAIDs). It is approved for veterinary use in dogs and horses, primarily for the management of pain and inflammation associated with osteoarthritis, as well as for perioperative pain and chronic musculoskeletal disorders. Firocoxib acts by selectively inhibiting COX-2-mediated prostaglandin synthesis, resulting in analgesic, anti-inflammatory, and antipyretic effects. Its selectivity for COX-2 over COX-1 reduces the risk of gastrointestinal side effects commonly seen with non-selective NSAIDs. Firocoxib was the first COX-2 inhibitor approved by the FDA for use in horses. It is not intended or approved for human medicine[3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on firocoxib.